Patent 7759390 was granted and assigned to Novartis on July, 2010 by the United States Patent and Trademark Office.
Compounds of formula I, wherein one of R1 and R2 is thienyl which is substituted by halogen and the other of R1 and R2 is substituted phenyl, wherein the substituents are as defined in the claims, with the proviso that the phenyl group is substituted by at least a cyano, carboxy or (C1-4)alkyloxycarbonyl group, are inhibitors of CCR9 activity and useful for therapeutic treatment.